Your browser is no longer supported. Please, upgrade your browser.
ATNX Athenex, Inc. daily Stock Chart
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own7.10% Shs Outstand92.53M Perf Week-5.58%
Market Cap657.89M Forward P/E- EPS next Y-0.90 Insider Trans17.98% Shs Float55.10M Perf Month-43.12%
Income-123.70M PEG- EPS next Q-0.17 Inst Own54.20% Short Float17.12% Perf Quarter-54.74%
Sales101.20M P/S6.50 EPS this Y8.10% Inst Trans0.13% Short Ratio13.81 Perf Half Y-42.66%
Book/sh2.40 P/B2.96 EPS next Y40.40% ROA-43.40% Target Price28.22 Perf Year-37.85%
Cash/sh1.74 P/C4.09 EPS next 5Y- ROE-79.70% 52W Range5.63 - 21.11 Perf YTD-53.44%
Dividend- P/FCF- EPS past 5Y-39.10% ROI-49.90% 52W High-66.32% Beta-
Dividend %- Quick Ratio2.80 Sales past 5Y142.30% Gross Margin31.20% 52W Low26.29% ATR1.00
Employees574 Current Ratio3.20 Sales Q/Q61.50% Oper. Margin- RSI (14)37.83 Volatility11.32% 13.87%
OptionableYes Debt/Eq0.28 EPS Q/Q31.70% Profit Margin- Rel Volume0.85 Prev Close8.06
ShortableYes LT Debt/Eq0.28 EarningsFeb 27 BMO Payout- Avg Volume682.79K Price7.11
Recom1.70 SMA20-11.97% SMA50-38.64% SMA200-49.83% Volume580,880 Change-11.79%
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Mar-13-20 08:10AM  Athenex Provides a Corporate Update GlobeNewswire
Mar-11-20 07:06AM  Edited Transcript of ATNX earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents -7.74%
Mar-10-20 07:05PM  Needham: Our Best 3 Top Ideas for COVID-19 Stabilization TipRanks +6.73%
Mar-09-20 07:00AM  Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis GlobeNewswire -15.87%
Mar-06-20 12:00PM  Athenex (ATNX) Moves to Buy: Rationale Behind the Upgrade Zacks -6.72%
Mar-02-20 10:19AM  Athenexs Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis GlobeNewswire +5.48%
Feb-27-20 10:15AM  Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM  Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update GlobeNewswire
06:00AM  Athenex, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-20 08:00AM  Athenex Announces Participation at the Cowen 40th Annual Health Care Conference GlobeNewswire
Feb-20-20 12:31PM  Earnings Preview: Athenex (ATNX) Q4 Earnings Expected to Decline Zacks
Feb-06-20 07:00AM  Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020 GlobeNewswire
Feb-03-20 05:01PM  Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma GlobeNewswire
Jan-16-20 09:46AM  Moving Average Crossover Alert: Athenex Zacks
05:58AM  Athenex (NASDAQ:ATNX) Shareholders Have Enjoyed A 30% Share Price Gain Simply Wall St.
Jan-08-20 01:51PM  WNY factory rundown: Sealing Devices looks west, Athenex update and Servotronics growth American City Business Journals
Dec-28-19 05:17PM  Notable Insider Buys In The Past Week: Athenex And Humana Benzinga
Dec-27-19 02:57PM  Insiders Roundup: Nike, Eastman Kodak GuruFocus.com
Dec-22-19 01:52PM  Hedge Funds Have Never Been This Bullish On Athenex, Inc. (ATNX) Insider Monkey
Dec-16-19 07:00AM  Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao GlobeNewswire -6.74%
Dec-13-19 09:46AM  Athenex shares fall 19% in morning trading MarketWatch -14.21%
09:31AM  Faruqi & Faruqi, LLP is Investigating Athenex, Inc. (ATNX) on Behalf of its Shareholders PR Newswire
08:30AM  Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer GlobeNewswire
Dec-11-19 07:00AM  Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019 GlobeNewswire
Dec-09-19 08:10PM  Bytes and pieces: Extended thoughts from Armory Square Ventures leader; more news from Launch NY American City Business Journals -6.17%
Dec-05-19 08:00AM  Athenex Announces $60 Million Private Placement GlobeNewswire
Dec-02-19 05:00AM  Edited Transcript of ATNX earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents
Nov-21-19 08:42AM  Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock? Zacks
Nov-19-19 09:05AM  Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium GlobeNewswire +35.66%
Nov-18-19 03:29AM  Edited Transcript of ATNX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 08:35AM  Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM  Athenex, Inc. Announces Third Quarter 2019 Financial Results GlobeNewswire
Oct-31-19 10:34AM  Earnings Preview: Athenex (ATNX) Q3 Earnings Expected to Decline Zacks
Oct-30-19 07:00AM  Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma GlobeNewswire
Oct-28-19 03:30AM  Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment GlobeNewswire
Oct-26-19 12:33PM  Hedge Funds Have Never Been More Bullish On Athenex, Inc. (ATNX) Insider Monkey
Oct-24-19 07:00AM  Athenex, Inc. to Report Third Quarter 2019 Earnings Results on November 7, 2019 GlobeNewswire
07:00AM  Athenex Provides An Update to Shareholders GlobeNewswire
Oct-21-19 04:46PM  Weekly CFO Buys Highlight GuruFocus.com -6.16%
11:29AM  Weekly CEO Buys Highlight GuruFocus.com
Oct-18-19 06:49AM  Should You Be Worried About Insider Transactions At Athenex, Inc. (NASDAQ:ATNX)? Simply Wall St. -5.28%
Oct-10-19 10:34PM  Edited Transcript of ATNX earnings conference call or presentation 7-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 12:14PM  Weekly CEO Buys Highlight GuruFocus.com
Sep-30-19 11:44AM  Weekly CEO Buys Highlight GuruFocus.com
Sep-23-19 07:00AM  Athenex to Present at the 2019 San Antonio Breast Cancer Symposium GlobeNewswire
07:00AM  Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019 GlobeNewswire
07:00AM  Athenex Completes Construction of New API Facility in Chongqing GlobeNewswire
Sep-22-19 04:44PM  Weekly CEO Buys Highlight GuruFocus.com
Sep-13-19 05:15AM  Chief scientist: David Hangauer talks about the creation of Athenex American City Business Journals
Sep-12-19 07:15AM  Is Athenex (NASDAQ:ATNX) Using Debt Sensibly? Simply Wall St.
Sep-11-19 07:00AM  Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical GlobeNewswire
Sep-04-19 07:00AM  Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy GlobeNewswire
Aug-27-19 12:00PM  7 Stocks the Insiders Are Buying on Sale InvestorPlace -6.01%
Aug-23-19 06:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $74,900 of Shares GuruFocus.com
Aug-17-19 06:40PM  Top Insider Buys Highlight for the Week of Aug. 16 GuruFocus.com
Aug-13-19 06:04AM  Analyst: Athenex drug trial results showcased 'significant commercial potential' American City Business Journals
Aug-07-19 07:23PM  Athenex, Inc. (ATNX) Q2 2019 Earnings Call Transcript Motley Fool -20.23%
04:17PM  Why This Highflying Biotech With A 50% Gain For 2019 Just Crashed Investor's Business Daily
03:46PM  Phase III results are in for Athenex's leading drug candidate, but reaction is varied American City Business Journals
07:35AM  Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:00AM  Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance GlobeNewswire
06:00AM  Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer GlobeNewswire
05:58AM  Do Insiders Own Shares In Athenex, Inc. (NASDAQ:ATNX)? Simply Wall St.
Aug-02-19 08:00AM  Athenex Provides an Update Regarding the Vasopressin Case GlobeNewswire
Jul-31-19 10:36AM  Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-29-19 08:00AM  Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019 GlobeNewswire
Jul-09-19 11:23AM  Athenex (ATNX) in Focus: Stock Moves 6.5% Higher Zacks
Jun-28-19 07:00AM  Athenex Announces Strategic Global Initiatives to Expand Clinical Operations GlobeNewswire +7.67%
Jun-27-19 08:00AM  SunGen Pharma Announces to Partner with Athenex Pharmaceutical to Launch Bivalirudin through PIV Challenges in US GlobeNewswire
Jun-24-19 07:00AM  Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase) GlobeNewswire
Jun-23-19 07:30AM  A Biotech Pro Loaded Up on These 2 Stocks Barrons.com
Jun-10-19 06:06PM  Athenex Rallies on Positive Early Data on Psoriasis Candidate Zacks
05:30PM  Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug Zacks
Jun-06-19 07:00AM  Athenex Provides an Update on its Chongqing API Plant GlobeNewswire
07:00AM  Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis GlobeNewswire
May-30-19 07:00AM  Athenex to Present at the 2019 ASCO Annual Meeting GlobeNewswire
May-09-19 03:23PM  Athenex, Inc. (ATNX) Q1 2019 Earnings Call Transcript Motley Fool
09:07AM  Athenex: 1Q Earnings Snapshot Associated Press
May-06-19 04:31PM  Why Bausch Health Companies, Aquantia, and Athenex Jumped Today Motley Fool +28.36%
10:20AM  Athenex just raised $100 million. Here's what it means American City Business Journals
08:00AM  Athenex Announces $100 Million Private Placement GlobeNewswire
May-05-19 01:44PM  Hedge Funds Have Never Been This Bullish On Athenex, Inc. (ATNX) Insider Monkey
May-03-19 09:12AM  Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma GlobeNewswire
Apr-25-19 07:00AM  Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019 GlobeNewswire
Apr-23-19 07:00AM  Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Apr-02-19 07:00AM  Athenex Announces Appointment of John Koh as a New Board Member GlobeNewswire
Apr-01-19 01:20PM  Weekly CEO Buys Highlight GuruFocus.com
Mar-29-19 04:15PM  Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors GlobeNewswire
09:15AM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares GuruFocus.com
Mar-28-19 07:00AM  Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited GlobeNewswire
Mar-27-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares GuruFocus.com
Mar-26-19 07:15AM  New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-25-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,500 of Shares GuruFocus.com
Mar-21-19 08:30AM  Athenex Announces Xiangxue Life Sciences Receives IND Allowance from Chinas National Medical Products Administration for Cancer Immunotherapy Drug Candidate GlobeNewswire
08:30AM  Athenex Announces Expansion of Board of Directors GlobeNewswire
Mar-20-19 09:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $126,000 of Shares GuruFocus.com
Mar-19-19 08:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $226,212 of Shares GuruFocus.com
Mar-15-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $141,240 of Shares GuruFocus.com
Mar-14-19 01:29AM  Edited Transcript of ATNX earnings conference call or presentation 11-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 12:04PM  The moment Athenex executives and investors have been waiting for is almost here American City Business Journals
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 27Buy7.881,0007,8803,112,959Mar 27 04:30 PM
Sze RandollChief Financial OfficerMar 27Buy8.191,0008,1905,000Mar 27 04:14 PM
Fok MansonDirectorMar 25Buy7.2550,000362,5001,969,609Mar 26 05:07 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 23Buy6.641,0006,6403,111,959Mar 23 04:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 20Buy6.851,0006,8503,110,959Mar 20 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Buy6.602,00013,2003,109,959Mar 19 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 18Buy5.782,00011,5603,107,959Mar 18 04:11 PM
Kwan RudolfEVP, Chief Medical OfficerMar 18Buy5.904,00023,584141,048Mar 19 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Buy6.902,00013,8003,105,959Mar 17 04:42 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 16Buy7.612,00015,2203,103,959Mar 16 04:11 PM
TSANG Benson Kwan HungDirectorMar 13Buy8.395,00041,95010,000Mar 16 06:55 AM
Kwan RudolfEVP, Chief Medical OfficerMar 12Buy8.192,00016,380137,048Mar 13 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.122,00016,2403,101,959Mar 13 04:13 PM
TSANG Benson Kwan HungDirectorMar 12Buy8.345,00041,7005,000Mar 13 05:23 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.354,00033,3963,099,959Mar 12 04:11 PM
YORDON JEFFREYSee RemarksMar 12Buy8.1410,00081,430218,926Mar 12 04:15 PM
Fok MansonDirectorMar 11Buy10.2850,000513,8501,919,609Mar 11 04:21 PM
Kwan RudolfEVP, Chief Medical OfficerMar 09Buy9.792,00019,573135,048Mar 10 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 24Buy14.3973,6981,060,51411,532,467Dec 27 04:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 23Buy14.30153,2372,191,28911,458,769Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 20Buy14.14189,3222,677,01311,305,532Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 19Buy13.78263,7433,635,48411,116,210Dec 26 06:04 AM
WU JINNDirectorDec 18Option Exercise4.5520,00091,000371,208Dec 19 04:09 PM
Sze RandollChief Financial OfficerDec 17Buy13.251,00013,2504,000Dec 17 04:11 PM
WU JINNDirectorDec 16Option Exercise4.5530,000136,500351,208Dec 18 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 16Option Exercise4.5515,00068,2503,095,959Dec 17 04:08 PM
Fok MansonDirectorNov 07Buy11.6750,000583,5001,869,609Nov 12 04:06 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 22Option Exercise4.555,00022,7503,080,959Oct 23 08:03 AM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 21Option Exercise4.5510,00045,5003,075,959Oct 22 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 17Option Exercise4.5510,00045,5003,065,959Oct 18 04:05 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 17Buy10.9350,000546,50010,852,467Oct 21 06:00 PM
Sze RandollChief Financial OfficerOct 17Buy10.991,00010,9903,000Oct 17 04:11 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 16Buy10.2967,222691,71410,802,467Oct 18 06:00 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 16Buy10.166,00060,9603,055,959Oct 16 04:30 PM
Sze RandollChief Financial OfficerSep 30Buy12.621,00012,6202,000Sep 30 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 27Buy12.853,00038,5503,049,959Sep 30 04:08 PM
Kwan RudolfEVP, Chief Medical OfficerSep 25Option Exercise4.5524,000109,200132,106Sep 25 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 23Buy13.865,00069,3003,046,959Sep 23 04:08 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 16Buy13.5830,000407,40010,735,245Sep 18 05:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 16Buy13.575,00067,8503,041,959Sep 16 04:25 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 13Buy14.2756,416805,05610,705,245Sep 16 07:31 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 12Buy14.0513,584190,85510,648,829Sep 16 07:31 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 23Buy14.985,00074,9003,036,959Aug 23 04:08 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 16Buy14.9620,000299,20010,635,245Aug 16 05:31 PM
Kwan RudolfEVP, Chief Medical OfficerAug 15Buy14.851,00014,850108,106Aug 16 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 15Buy14.9010,000149,0003,031,959Aug 15 04:14 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 15Buy15.0030,000450,00010,615,245Aug 16 05:31 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 08Buy15.7630,000472,80010,585,245Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 07Buy14.43733,12710,576,25110,555,245Aug 09 05:55 PM
Davis Stephanie ADirectorJun 26Buy18.0010,000180,00010,000Jun 27 08:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 25Buy17.891,49526,7469,822,118Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 24Buy17.9020,786372,0699,820,623Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 21Buy17.8523,073411,8539,799,837Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 18Buy17.7350,742899,6569,776,764Jun 20 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 17Buy17.94130,0002,332,2009,726,022Jun 19 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 14Buy17.69324,2905,736,6909,596,022Jun 18 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 13Buy17.0575,7101,290,8569,271,732Jun 17 08:00 PM
Kanfer JordanDirectorJun 06Buy15.012,50037,5254,184Jun 07 04:16 PM
PERCEPTIVE ADVISORS LLC10% OwnerMay 06Buy12.71100,0001,271,1489,196,022May 08 05:04 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardApr 24Option Exercise4.5510,00045,5003,021,959Apr 25 04:08 PM